drugset / Trial / NCT03732950
Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
Phase 2
Active not recruiting
5 enrolled
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well pembrolizumab works in treating participants with ovarian cancer that has come back after previous treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Timeline
- Start
- 2019-03-06
- Primary completion
- 2023-12-05
- Completion
- 2025-03-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |